Author

Wenying Huang

Observed names: W. Huang, W.T. Huang, Wen-ying HUANG

Institution: Zigong First People's Hospital

Observed institutions: Prothena (United States), MEI Pharma (United States), Zigong First People's Hospital

OpenAlex ID: A5037345577

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

2012 · Vanita R. Aroda, Robert R. Henry, et al. · Clinical Therapeutics · 251

Clinical Effects of Long-Term Metreleptin Treatment in Patients With Lipodystrophy

2011 · Jean L. Chan, Karen Lutz, et al. · Endocrine Practice · 145

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

2012 · Börje Darpö, Sager Philip, et al. · British Journal of Clinical Pharmacology · 35

Relationship between neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio and osteoporosis in postmenopausal type 2 diabetic patients: A retrospective study

2024 · Yuan Xue, Weichao Bao, et al. · Medicine · 11

Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

2021 · Wojciech Jurczak, Pier Luigi Luigi Zinzani, et al. · Blood · 5

6518 Evaluation of vandetanib in patients with inoperable hepatocellular carcinoma (HCC): a randomized, double-blind, parallel group, multicentre, Phase II study

2009 · C. Hsu, T.S. Yang, et al. · European Journal of Cancer Supplements · 5

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

2023 · Vaishali Sanchorawala, Ashutosh D Wechalekar, et al. · Blood · 2

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

2021 · Wojciech Jurczak, Pier Luigi Zinzani, et al. · Journal of Clinical Oncology · 2

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

2021 · Jacob Drobnyk Soumerai, Deepa Jagadeesh, et al. · Journal of Clinical Oncology · 1

Fracture and migration of a peripherally inserted central catheter: A case report

2025 · Wenying Huang, Wenping Li, et al. · Asian Journal of Surgery

P1114: Zandelisib on Intermittent Dosing as a Single Agent or in Combination With Rituximab or Zanubrutinib in Relapsed/refractory (r/r) Follicular Lymphoma (fl): Results From a Multi-arm Phase 1b Study

2022 · J. D. Soumerai, D. Jagadeesh, et al. · HemaSphere

Targeted distribution of flurbiprofen axetil in hysteromyoma and its influence on prostaglandin E 2

2015 · Wen-ying HUANG, Li CHEN, et al. · Academic Journal of Second Military Medical University

“Druggable” alterations detected by ion torrent in metastasis colorectal cancer patients.

2013 · Weijia Fang, Milan Radovich, et al. · Journal of Clinical Oncology

Late-Breaking Clinical Trial Report

2011 · Jean L. Chan, Karen Lutz, et al.

Works count: 14

Citation count: 457

H-index: 5

I10-index: 4